Voices
Enrique Grande
Enrique Grande/mdandersonhospiten.es

Enrique Grande: Promising Results from First-in-Human Nectin-4 Bicycle Drug Conjugate Study

Enrique Grande, Medical Oncology Department Director at Quironsalud Madrid, Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“JCO ASCO: First-in-human Nectin-4 Bicycle Drug Conjugate (zelenectide pevedotin/BT8009) shows manageable safety and encouraging activity—especially in urothelial cancer.

Short half-life vs ADCs could make combos easier. Doses selected; expansion ongoing.”

Title: First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

Authors: Capucine Baldini, Loic Verlingue, Vincent Goldschmidt, Bernard Doger de Spéville, Julia Lostes, Antoine Italiano, Sophie Cousin, Gerald S. Falchook, Andrea Necchi, Oscar Reig Torras, Elisa Fontana, Louise Carter, Jordi Rodon Ahnert, Jason R. Brown, Leslie R. DeMars, Kate Josephs, Amy Dickson, Cong Xu, Justin Bader, Carly Campbell, Rajiv Sharma, Meredith McKean

Read the full article on Journal of Clinical Oncology.

Enrique Grande: Promising Results from First-in-Human Nectin-4 Bicycle Drug Conjugate Study

Read more posts featuring Enrique Grande on OncoDaily.

Amy Dickson Andrea Necchi Antoine Italiano Bernard Doger De-Speville cancer Capucine Baldini Carly Campbell Cong Xu Elisa Fontana Enrique Grande Gerald S. Falchook Jason R. Brown Jordi Rodon Ahnert Julia Lostes Justin Bader Kate Josephs Leslie R. DeMars Loic Verlingue Louise Carter Meredith McKean OncoDaily Oncology Oscar Reig Torras Rajiv Sharma Sophie Cousin Vincent Goldschmidt